Tuan Nguyen is the Chief Financial Officer at Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company pioneering RNA interference (RNAi) therapeutics for liver diseases, including chronic Hepatitis B. Appointed in September 2020, he leads the company's financial strategy, overseeing budgeting, forecasting, treasury management, investor relations, and capital raising efforts. His role is pivotal in supporting Arbutus's advancement of its proprietary Lipid Nanoparticle (LNP) delivery platform and clinical pipeline, ensuring financial stability amid the high-risk, high-reward biotech landscape. With over 20 years of experience in biotechnology and pharmaceuticals, Tuan previously served as CFO at Zymeworks Inc. from 2017 to 2020, where he orchestrated the company's dual IPO on the NYSE and TSX, raising over $300 million, and facilitated key partnerships and expansions. Earlier, he was Vice President of Finance at Aurinia Pharmaceuticals Inc., contributing to its growth through public listings and financings, and held senior finance roles at IntraImmune Therapies Inc. and Lorus Therapeutics Inc., managing equity offerings, M&A transactions, and operational turnarounds that secured hundreds of millions in funding. Tuan's achievements include navigating complex capital markets, optimizing financial structures for R&D-intensive firms, and driving value creation in volatile sectors. At Arbutus, he has spearheaded strategic financings exceeding $100 million since joining, bolstering the balance sheet and enabling progression of key assets like AB-729 and AB-836 into clinical development, positioning the company for potential breakthroughs in RNAi-based treatments.